Russell Investments Group
KRYS icon

Russell Investments Group’s Krystal Biotech KRYS Stock Holding History

Russell Investments Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.77M Sell
26,210
-2,744
-9% -$730K 0.01% 1167
2025
Q4 		$7.14M Buy
28,954
+2,405
+9% +$506K 0.01% 1103
2025
Q3 		$4.69M Buy
26,549
+16,191
+156% +$2.42M 0.01% 1353
2025
Q2 		$1.42M Sell
10,358
-27,423
-73% -$4.03M ﹤0.01% 1892
2025
Q1 		$6.81M Buy
37,781
+37,336
+8,390% +$6.28M 0.01% 1002
2024
Q4 		$69.7K Buy
445
+15
+3% +$2.66K ﹤0.01% 2753
2024
Q3 		$78.3K Sell
430
-850
-66% -$164K ﹤0.01% 2706
2024
Q2 		$235K Buy
1,280
+569
+80% +$95.5K ﹤0.01% 2437
2024
Q1 		$127K Sell
711
-24,768
-97% -$3.44M ﹤0.01% 2532
2023
Q4 		$3.16M Sell
25,479
-13,219
-34% -$1.47M 0.01% 1367
2023
Q3 		$4.49M Buy
38,698
+5,745
+17% +$701K 0.01% 1135
2023
Q2 		$3.87M Buy
32,953
+10,341
+46% +$1.06M 0.01% 1202
2023
Q1 		$1.81M Buy
+22,612
New +$1.78M ﹤0.01% 1649

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group's KRYS Position: Q1 2026 in Review

Russell Investments Group reduced its Krystal Biotech (KRYS) stake by 9.5% in Q1 2026, selling an estimated $730K and leaving 26,210 shares worth $6.77M. The position accounts for 0.01% of the portfolio, ranked #1167.

Russell Investments Group first reported a position in KRYS in Q1 2023 and has held it in 13 quarters since. The position peaked at $7.14M in Q4 2025. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Russell Investments Group held 26,210 shares of Krystal Biotech worth $6.77M as of Q1 2026.
  • Russell Investments Group sold 2,744 Krystal Biotech shares in Q1 2026, an estimated $730K.
  • Krystal Biotech made up 0.01% of Russell Investments Group's portfolio in Q1 2026, its #1167 holding.
  • Russell Investments Group first reported a position in Krystal Biotech in Q1 2023 and has held it in 13 quarters since.
  • Russell Investments Group's Krystal Biotech position peaked at $7.14M in Q4 2025.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Russell Investments Group's 13F filing for Q1 2026, filed 8 May 2026.